Fingerprint
Dive into the research topics of 'Atorvastin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM patients: Multicenter, open label study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Atorvastin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM patients: Multicenter, open label study
Gvalencia, C. Posadas, F. Gómez Pérez, C. Vázquez, E. Meaney
Research output: Contribution to journal › Article › peer-review